Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cerus Corporation    CERS

CERUS CORPORATION

(CERS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2021 01/21/2021 01/22/2021 01/25/2021 01/26/2021 Date
7.285(c) 7.23(c) 7.26(c) 7.28(c) 6.95 Last
1 836 747 1 439 016 1 197 376 1 534 080 1 287 928 Volume
+0.07% -0.75% +0.41% +0.28% -4.53% Change
More quotes
Financials (USD)
Sales 2020 90,7 M - -
Net income 2020 -60,1 M - -
Net Debt 2020 - - -
P/E ratio 2020 -19,8x
Yield 2020 -
Sales 2021 107 M - -
Net income 2021 -54,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -22,4x
Yield 2021 -
Capitalization 1 217 M 1 217 M -
Capi. / Sales 2020 13,4x
Capi. / Sales 2021 11,3x
Nbr of Employees 254
Free-Float 97,9%
More Financials
Company
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The... 
More about the company
Notations Surperformance© of Cerus Corporation
Trading Rating : Investor Rating :
More Ratings
All news about CERUS CORPORATION
01/11CERUS : Preliminary Q4 Product Revenue Rises 35% From Year Ago, Sets Guidance
MT
01/11CERUS CORP : Results of Operations and Financial Condition, Financial Statements..
AQ
01/11CERUS CORPORATION : Announces Preliminary Fourth Quarter and Full Year 2020 Prod..
BU
01/06CERUS CORP : Creation of a Direct Financial Obligation or an Obligation under an..
AQ
2020CERUS : Unit Lands 3-Year Blood System Supply Deal in Brazil
MT
2020CERUS : rsquo; Distribution Partner, CEI, Announces Three-Year Tender Award with..
BU
2020CERUS : Plans Sale of up to $100 Million of Common Shares
MT
2020CERUS CORP : Entry into a Material Definitive Agreement, Financial Statements an..
AQ
2020CERUS CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020CERUS CORPORATION : Announces Presentation of Study Results with INTERCEPT-treat..
BU
2020SECTOR UPDATE : Health Care Stocks Unable to Return to Positive Ground by Close
MT
2020SECTOR UPDATE : Health Care Stocks Swinging Between Small Gains, Losses
MT
2020SECTOR UPDATE : Health Care
MT
2020Equities Retreat in Early US Trading as Benchmarks Cap Strong November With W..
MT
2020Cerus Secures FDA's Approval For System Intended to Treat Bleeding Disorders;..
MT
More news
News in other languages on CERUS CORPORATION
2014CERUS CORPORATION : publication des résultats trimestriels
2013CERUS CORPORATION : publication des résultats trimestriels
2012CERUS CORPORATION : publication des résultats trimestriels
2007CERUS CORP : Cerus annonce avoir passé un accord portant sur la fourniture du sy..
2007CERUS CORP : INTERCEPT Plasma inscrit au Journal Officiel français
More news
Chart CERUS CORPORATION
Duration : Period :
Cerus Corporation Technical Analysis Chart | CERS | US1570851014 | MarketScreener
Technical analysis trends CERUS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 9,13 $
Last Close Price 7,28 $
Spread / Highest target 37,4%
Spread / Average Target 25,3%
Spread / Lowest Target 9,89%
EPS Revisions
Managers and Directors
NameTitle
William Mariner Greenman President, Chief Executive Officer & Director
Daniel N. Swisher Chairman
Vivek K. Jayaraman Chief Operating Officer
Kevin Dennis Green Chief Financial Officer & Vice President-Finance
Laurence M. Corash Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CERUS CORPORATION5.20%1 217
STRYKER CORPORATION-2.24%90 021
SMITH & NEPHEW PLC6.69%19 251
INSPIRE MEDICAL SYSTEMS, INC.14.27%5 789
VENUS MEDTECH (HANGZHOU) INC.20.24%5 186
GLAUKOS CORPORATION12.90%3 818